A Double-Blind Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Verstovsek, S.; Mesa, R.; Gotlib, J.; Levy, R.; Gupta, Vikas; Dipersio, J.; Catalano, J.; Deininger, M.; B. Miller, Carole; Silver, R.; Talpaz, M.; Winton, E.; Harvey, J.; Arcasoy, M.; Hexner, E.; Lyons, R.; Paquette, R.; Raza, A.; Vaddi, K.; Erickson-Viitanen, S.; Koumenis, I.; Sun, William; Sandor, V.; Kantarjian, H.

doi:10.1056/NEJMoa1110557

Public

A Double-Blind Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Shared by NobleBlocks on Mar 1, 2012 • 12:00 AM UTC

Authors:

S. Verstovsek

R. Mesa

J. Gotlib

Abstract

BACKGROUND Ruxolitinib, a selective JAK1 and JAK2 inhibitor, has clinically significant activity in myelofibrosis. METHODS In a double-blind trial, patients with intermediate-2 or high-risk myelofibrosis were randomized to twice-daily oral ruxolitinib (n=155) or placebo (n=154). The primary endpoint...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!